Financial reports
NT 10-Q
Notice of late quarterly filing
29 Jun 20
10-K
2019 FY
Annual report
1 Jun 20
NT 10-K
Notice of late annual filing
14 May 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
15 Aug 19
NT 10-Q
Notice of late quarterly filing
15 Aug 19
10-Q
2019 Q1
Quarterly report
14 May 19
10-K
2018 FY
Annual report
5 Mar 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
Current reports
8-K
Departure of Directors or Certain Officers
29 Jun 20
8-K
Other Events
14 May 20
8-K
Other Events
30 Mar 20
8-K
Other Events
27 Mar 20
8-K
Regulation FD Disclosure
27 Sep 19
8-K
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
23 Sep 19
8-K
Departure of Directors or Certain Officers
20 Sep 19
8-K
Regulation FD Disclosure
13 Sep 19
8-K
Entry into a Material Definitive Agreement
6 Sep 19
8-K
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
30 Aug 19
Registration and prospectus
15-15D
Suspension of duty to report
6 Jul 20
RW
Registration withdrawal request
6 Jul 20
25-NSE
Exchange delisting
23 Sep 19
D
$15M in equity / options / securities to be acquired
15 Jul 19
S-1
IPO registration
11 Jul 19
25-NSE
Exchange delisting
15 May 19
25-NSE
Exchange delisting
15 May 19
424B3
Prospectus supplement
3 May 19
Proxies
DEF 14A
Definitive proxy
6 Aug 19
PRE 14A
Preliminary proxy
26 Jul 19
DEF 14A
Definitive proxy
4 Mar 19
PRER14A
Preliminary revised proxy
4 Mar 19
PRE 14A
Preliminary proxy
22 Feb 19
DEF 14A
Definitive proxy
26 Nov 18
PREM14A
Preliminary proxy related to merger
2 Nov 18
DEFA14A
Additional proxy soliciting materials
19 Sep 18
DEFA14A
Additional proxy soliciting materials
13 Sep 18
Other
EFFECT
Notice of effectiveness
6 May 19
CT ORDER
Confidential treatment order
6 May 19
CORRESP
Correspondence with SEC
3 May 19
CORRESP
Correspondence with SEC
2 May 19
CORRESP
Correspondence with SEC
2 May 19
UPLOAD
Letter from SEC
2 May 19
CORRESP
Correspondence with SEC
29 Apr 19
CORRESP
Correspondence with SEC
15 Apr 19
UPLOAD
Letter from SEC
11 Apr 19
CORRESP
Correspondence with SEC
3 Apr 19
Ownership
SC 13G/A
Xynomic Pharmaceuticals Holdings, Inc.
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13D/A
Xynomic Pharmaceuticals Holdings, Inc.
6 Jun 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
30 May 19
3
Tingzhi Qian
30 May 19
3
Wentao Jason Wu
30 May 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
30 May 19
SC 13D
Xynomic Pharmaceuticals Holdings, Inc.
29 May 19
3
Yinglin Mark Xu
29 May 19
3
Jinwei Coco Kou
28 May 19